文献速递肺结节与肺癌

肺癌筛查中戒烟干预的优化随机临床试验:戒烟与筛查以拯救生命

An Optimization Randomized Clinical Trial to Identify an Effective, Efficient Smoking Cessation Intervention in the Context of Lung Cancer Screening: Cessation and Screening to Save Lives.
PubMed 文献 · Chest · 2026-07-08

CASTL优化随机临床试验在美国17个肺癌筛查点纳入758名50-80岁正在吸烟的筛查者,随机分配至16种戒烟干预组合。6个月随访时各干预组分间无显著差异,最具价值效率的组合为损失框架信息+尼古丁贴片/含片(预期戒断率30%,平均成本287.41美元)。

要点

  • 肺癌筛查是提供循证戒烟治疗的重要机会。
  • 损失框架信息联合尼古丁贴片/含片最具价值效率。
  • 仅增益框架信息是成本更低的替代方案。

核心结论

  • 肺癌筛查为有肺癌风险的吸烟者提供了提供循证戒烟治疗的良好机会。
  • 整合尼古丁替代联合疗法与简短危害沟通是改善戒断结局的有前景、价值高效且可行的选择。

研究设计与样本

  • CASTL为优化随机临床试验,在美国17个肺癌筛查点开展。
  • 纳入50至80岁、计划接受肺癌筛查且目前吸烟的参与者,随机分配至16种戒烟干预组分组合。
  • 干预组分包括增强标准照护、动机性访谈、尼古丁贴片/含片和消息框架。
  • 主要结局为6个月随访时自我报告的戒断。

主要发现

  • 入组758名参与者中,约5%对戒烟不感兴趣,59%正在考虑戒烟,38%已在改变吸烟行为。
  • 大多数(79%)报告醒来后30分钟内吸烟,表明尼古丁依赖程度高。
  • 各干预组分间无显著差异。
  • 损失框架信息+尼古丁贴片+含片预期戒断率为30%,平均成本287.41美元。
  • 成本更低的组合中,仅增益框架信息为价值高效替代方案,戒断率13%,成本51.29美元。

关键数值与推荐

  • 最具价值效率干预:损失框架信息+尼古丁贴片+含片,预期戒断率30%,平均成本287.41美元。
  • 低成本价值高效替代:仅增益框架信息,戒断率13%,成本51.29美元。
  • 各干预组分间戒断率无显著差异。

临床怎么用

  • 在肺癌筛查场景中可考虑提供尼古丁替代联合疗法联合简短危害沟通。
  • 对于资源有限场景,仅增益框架信息可作为低成本替代方案。

局限性

  • 未来试验应评估该有前景干预包的有效性实施。
  • 未来应研究在肺癌筛查场景中实施烟草使用治疗的可扩展策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 50% of the estimated 14 million people eligible for lung cancer screening (LCS) currently smoke. Gaps in knowledge regarding optimal tobacco treatment interventions in the context of LCS remain. RESEARCH QUESTION: What is the most value-efficient, evidence-based combination of tobacco treatment component(s) for people seeking LCS who smoke? STUDY DESIGN AND METHODS: Cessation and Screening to Save Lives (CASTL) is an optimization randomized clinical trial conducted at 17 LCS sites in the US. Eligible participants 50 to 80 years of age, scheduled for LCS, and currently smoking were randomized to 1 of 16 combinations of tobacco treatment components: enhanced standard care, motivational interviewing, nicotine patch/lozenge, and message framing. The primary outcome was self-reported abstinence at 6-month follow-up. The cost of each combination of components was estimated as a function of time and resources. RESULTS: Of the 758 participants at enrollment, about 5% of participants were not interested in quitting, 59% were considering quitting, and 38% already were making changes in their smoking. Most (79%) reported smoking within 30 minutes of waking, indicating a high nicotine dependence. Although there were no significant differences among the intervention components, the most value-efficient intervention with respect to expected abstinence was loss-framed messaging, nicotine patch, and lozenge (expected abstinence rate, 30%; mean cost, $287.41). Among the less-costly combinations, a value-efficient alternative included gain-framed messaging only (abstinence, 13%; cost, $51.29). INTERPRETATION: Our results show that LCS provides a compelling opportunity to provide evidence-based tobacco treatment to individuals at risk for lung cancer. Integrating combination nicotine replacement therapy and brief communication about the harms of smoking is a promising value-efficient, feasible option for improving cessation outcomes. Future trials should evaluate the effectiveness implementation of this promising package and examine scalable strategies for implementation of tobacco use treatment in LCS settings. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: 03315910; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Ostroff JS, Shelley D, Chichester LR, et al. An Optimization Randomized Clinical Trial to Identify an Effective, Efficient Smoking Cessation Intervention in the Context of Lung Cancer Screening: Cessation and Screening to Save Lives. Chest. 2026. PMID: 42419585. doi:10.1016/j.chest.2026.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。